Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma

Pigment Cell and Melanoma Research

Volumn 25, Issue 4, 2012, Pages 506-513

  Verma, Deepti ^a   Bivik, Cecilia ^a   Farahani, Ensieh ^a   Synnerstad, Ingrid ^a   Fredrikson, Mats ^a   Enerbäck, Charlotta ^a   Rosdahl, Inger ^a   Söderkvist, Peter ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

CIAS1; IL 1 ; Inflammasome; Melanoma; NLRP1; NLRP3; SNP

Indexed keywords

CARRIER PROTEIN; CRYOPYRIN; INFLAMMASOME; PROTEIN NLRP1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS REGULATORY PROTEINS; CARD SIGNALING ADAPTOR PROTEINS; CARRIER PROTEINS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMASOMES; INTERLEUKIN-18; INTERLEUKIN-1BETA; MALE; MELANOMA; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SKIN NEOPLASMS;

EID: 84862646126     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2012.01008.x     Document Type: Article

References (50)

1. Agostini, L., Martinon, F., Burns, K., Mcdermott, M.F., Hawkins, P.N., and Tschopp, J. (2004). NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319-325.
2. Aksentijevich, I., Nowak, M., Mallah, M. et al. (2002). e novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46, 3340-3348.
3. Aksentijevich, I., D Putnam, C., Remmers, E.F. et al. (2007). The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 56, 1273-1285.
4. Biswas, D.K., Singh, S., Shi, Q., Pardee, A.B., and Iglehart, J.D. (2005). crossroads of estrogen receptor and NF-kappaB signaling. Sci. STKE 2005, pe27.
5. Carmi, Y., Voronov, E., Dotan, S., Lahat, N., Rahat, M.A., Fogel, M., Huszar, M., White, M.R., Dinarello, C.A., and Apte, R.N. (2009). The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J. Immunol. 183, 4705-4714.
6. Chirivi, R.G., Garofalo, A., Padura, I.M., Mantovani, A., and Giavazzi, R. (1993). Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. Cancer Res. 53, 5051-5054.
7. Clevers, H. (2004). At the crossroads of inflammation and cancer. Cell 118, 671-674.
8. Coussens, L.M., and Werb, Z. (2001). Inflammatory cells and cancer: think different! J. Exp. Med. 193, F23-F26.
9. Coussens, L.M., and Werb, Z. (2002). Inflammation and cancer. Nature 420, 860-867.
10. Culig, Z., Hobisch, A., Herold, M. et al. (1998). Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. Br. J. Cancer 78, 1004-1011.
11. Diepgen, T.L., and Mahler, V. (2002). The epidemiology of skin cancer. Br. J. Dermatol. 146(Suppl 61), 1-6.
12. Dunn, J.H., Ellis, L.Z., and Fujita, M. (2012). Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett. 314, 24-33.
13. Englaro, W., Bahadoran, P., Bertolotto, C., Busca, R., Derijard, B., Livolsi, A., Peyron, J.F., Ortonne, J.P., and Ballotti, R. (1999). Tumor necrosis factor alpha-mediated inhibition of melanogenesis is dependent on nuclear factor kappa B activation. Oncogene 18, 1553-1559.
14. Fitzpatrick, T.B. (1988). The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 124, 869-871.
15. Fontalba, A., Gutierrez, O., Llorca, J., Mateo, I., Berciano, J., Fernandez-Luna, J.L., and Combarros, O. (2008). Deficiency of CARD8 is associated with increased Alzheimer's disease risk in women. Dement. Geriatr. Cogn. Disord. 26, 247-250.
16. Hoffman, H.M., and Simon, A. (2009). Recurrent febrile syndromes: what a rheumatologist needs to know. Nat. Rev. Rheumatol. 5, 249-256.
17. Jin, L., Yuan, R.Q., Fuchs, A. et al. (1997). Expression of interleukin-1beta in human breast carcinoma. Cancer 80, 421-434.
18. Jin, Y., Birlea, S.A., Fain, P.R., and Spritz, R.A. (2007a). Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J. Invest. Dermatol. 127, 2558-2562.
19. Jin, Y., Mailloux, C.M., Gowan, K., Riccardi, S.L., Laberge, G., Bennett, D.C., Fain, P.R., and Spritz, R.A. (2007b). NALP1 in vitiligo-associated multiple autoimmune disease. N. Engl. J. Med. 356, 1216-1225.
20. Kastbom, A., Verma, D., Eriksson, P., Skogh, T., Wingren, G., and Soderkvist, P. (2008). Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology (Oxford) 47, 415-417.
21. Keller, M., Ruegg, A., Werner, S., and Beer, H.D. (2008). Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818-831.
22. Kholmanskikh, O., Van Baren, N., Brasseur, F., Ottaviani, S., Vanacker, J., Arts, N., Van Der Bruggen, P., Coulie, P., and De Plaen, E. (2010). Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens. Int. J. Cancer 127, 1625-1636.
23. Lens, M.B., and Dawes, M. (2004). Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol. 150, 179-185.
24. Loffek, S., Zigrino, P., Angel, P., Anwald, B., Krieg, T., and Mauch, C. (2005). High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1alpha and basic fibroblast growth factor-mediated mechanisms. J. Invest. Dermatol. 124, 638-643.
25. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related inflammation. Nature 454, 436-444.
26. Martinon, F., Burns, K., and Tschopp, J. (2002). The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10, 417-426.
27. Oelmann, E., Kraemer, A., Serve, H., Reufi, B., Oberberg, D., Patt, S., Herbst, H., Stein, H., Thiel, E., and Berdel, W.E. (1997). Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. Int. J. Cancer 71, 1066-1076.
28. Okamoto, M., Liu, W., Luo, Y., Tanaka, A., Cai, X., Norris, D.A., Dinarello, C.A., and Fujita, M. (2010). Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J. Biol. Chem. 285, 6477-6488.
29. Park, H., Byun, D., Kim, T.S. et al. (2001). Enhanced IL-18 expression in common skin tumors. Immunol. Lett. 79, 215-219.
30. Pathan, N., Marusawa, H., Krajewska, M. et al. (2001). TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer. J. Biol. Chem. 276, 32220-32229.
31. Pollack, L.A., Li, J., Berkowitz, Z., Weir, H.K., Wu, X.C., Ajani, U.A., Ekwueme, D.U., Li, C., and Pollack, B.P. (2011). Melanoma survival in the United States, 1992 to 2005. J. Am. Acad. Dermatol. 65, S78-S86.
32. Qin, Y., Ekmekcioglu, S., Liu, P., Duncan, L.M., Lizee, G., Poindexter, N., and Grimm, E.A. (2011). Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol. Cancer Res. 9, 1537-1550.
33. Razmara, M., Srinivasula, S.M., Wang, L., Poyet, J.L., Geddes, B.J., Distefano, P.S., Bertin, J., and Alnemri, E.S. (2002). CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis. J. Biol. Chem. 277, 13952-13958.
34. Roberts, R.L., Topless, R.K., Phipps-Green, A.J., Gearry, R.B., Barclay, M.L., and Merriman, T.R. (2010). Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes Immun. 11, 351-356.
35. Roberts, R.L., Van Rij, A.M., Phillips, L.V., Young, S., Mccormick, S.P., Merriman, T.R., and Jones, G.T. (2011). Interaction of the inflammasome genes CARD8 and NLRP3 in abdominal aortic aneurysms. Atherosclerosis 218, 123-126.
36. Saijo, Y., Tanaka, M., Miki, M. et al. (2002). Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J. Immunol. 169, 469-475.
37. Schaefer, T.M., Wright, J.A., Pioli, P.A., and Wira, C.R. (2005). IL-1beta-mediated proinflammatory responses are inhibited by estradiol via down-regulation of IL-1 receptor type I in uterine epithelial cells. J. Immunol. 175, 6509-6516.
38. Schoultz, I., Verma, D., Halfvarsson, J. et al. (2009). Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am. J. Gastroenterol. 104, 1180-1188.
39. Schroder, K., and Tschopp, J. (2010). The inflammasomes. Cell 140, 821-832.
40. Synnerstad, I., Nilsson, L., Fredrikson, M., and Rosdahl, I. (2004). Frequency and distribution pattern of melanocytic naevi in Swedish 8-9-year-old children. Acta Derm. Venereol. 84, 271-276.
41. Tu, C.X., Gu, J.S., and Lin, X.R. (2003). Increased interleukin-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. J. Dermatol. Sci. 31, 73-78.
42. Van Deventer, H.W., Burgents, J.E., Wu, Q.P., Woodford, R.M., Brickey, W.J., Allen, I.C., Mcelvania-Tekippe, E., Serody, J.S., and Ting, J.P. (2010). The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res. 70, 10161-10169.
43. Verma, D., Lerm, M., Blomgran Julinder, R., Eriksson, P., Soderkvist, P., and Sarndahl, E. (2008). Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases? Arthritis Rheum. 58, 888-894.
44. Verma, D., Sarndahl, E., Andersson, H., Eriksson, P., Fredrikson, M., Jonsson, J.I., Lerm, M., and Söderkvist, P. (2012). The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1Β and IL-18 production. PLoS ONE 7, e34977.
45. Vidal-Vanaclocha, F., Amezaga, C., Asumendi, A., Kaplanski, G., and Dinarello, C.A. (1994). Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res. 54, 2667-2672.
46. Vidal-Vanaclocha, F., Alvarez, A., Asumendi, A., Urcelay, B., Tonino, P., and Dinarello, C.A. (1996). Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. J. Natl Cancer Inst. 88, 198-205.
47. Villani, A.C., Lemire, M., Fortin, G. et al. (2009). Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat. Genet. 41, 71-76.
48. Voronov, E., Shouval, D.S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C.A., and Apte, R.N. (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl Acad. Sci. USA 100, 2645-2650.
49. Wagner, R.N., Proell, M., Kufer, T.A., and Schwarzenbacher, R. (2009). Evaluation of Nod-like receptor (NLR) effector domain interactions. PLoS ONE 4, e4931.
50. Zitvogel, L., Kepp, O., Galluzzi, L., and Kroemer, G. (2012). Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 13, 343-351.